AssayIndex

AX-2026-041243

Retatrutide · 30 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2510-H1662

MARGINALVERIFIED
Report ID
AX-2026-041243
Compound
Retatrutide
Compound class
Incretin analogues and co-agonists
Supplier
WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Batch / lot
WWB-2510-H1662
Declared label claim
30mg
Laboratory
Janoshik Analytical
Assay date
09 Jan 2026
Submitted
23 Jan 2026
Quarter
2026-Q1
Submitter
k.petrescu
Sample provenance
Buyer-sourced
Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.05% area≥ 96.5PASS
Total impuritiesRP-HPLC, sum of reported peaks0.95% area≤ 3.5PASS
Largest single impurityRP-HPLC — des-Aib20 analogue0.41% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula4728.4871Da—NOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)4728.5107Da—NOT TESTED
Mass accuracyobserved vs theoretical+5.0ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance88.25%w/w—NOT TESTED
Target-compound contenttotal peptide content × purity87.41%w/w—NOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen36.05mg30 mg declaredNOT TESTED
Recovered target peptidegross fill × target content31.511mg30 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim105.0%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate4.77%≤ 8.0PASS
Counter-ion (TFA)anion-exchange ion chromatography6.01%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.97%—NOT TESTED
Endotoxinkinetic chromogenic LAL0.71EU/mg≤ 5.0PASS
Sterilitymembrane filtration, USP <71>, 14 dNo growth at 14 d—no growthPASS
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intact—white to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureSlow dissolution, >5 min to clarity—clear, no visible particulatesFAIL
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration3.56—2.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient19.89min20.71 ± 0.50 (normalised)FAIL
Peak asymmetry (10 % height)Ph. Eur. 2.2.460.95—0.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²68,013—≥ 20,000PASS
Resolution to nearest impurityvs [D-Aib2]-diastereomer0.70—no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

01542308446266168 Retatrutide19.89 min · 99.05 % 19.4524.01 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 68,013, and skew follows the reported asymmetry factor of 0.95. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.41 % impurity against a 99.05 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1Retatrutide — main peak19.894,814,13799.05—
2des-Aib20 analogue19.4519,9270.41-85.053
3[D-Aib2]-diastereomer19.6713,6090.280.000
4truncated (5-39)17.977,7760.16-428.201
5oxidised Trp (+16 Da)19.232,4300.05+15.995
6retatrutide dimer24.012,4300.05+4728.487
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4728.4871 Da, computed from C221H342N46O68. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100550750950115013501550 [M+5H]5+946.71[M+4H]4+1183.13[M+6H]6+789.09 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4728.5107 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
7+676.5054676.50880.00349.2
6+789.0885789.09240.003953.2
5+946.7047946.70940.0047100.0
4+1183.12911183.13500.005956.2
3+1577.16961577.17750.00798.6
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer4.77
Counter-ion (TFA)ion chromatography6.01
Residual solvent + inorganic residueestimated0.97
Total peptide contentby difference88.25
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.3499.05divergence +0.07 pp vs batch median
Total impurities (% area)not stated0.95
Largest single impurity (% area)not stated0.41
Water (%)4.24.77
Counter-ion (%)not stated6.01
Peptide content (%w/w)not stated88.25
Endotoxin (EU/mg)1.090.71
Method stated on certificateYES—column, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Buyer-sourced
Evidentiary weight
Strongest available evidence in this index.
Chain of custody
Retail purchase → submitter (ambient, 19 d) → laboratory (hand-carried, 10 d) → assay.
Assay date
09 Jan 2026
Submitted to the index
23 Jan 2026
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

survodutide_mixup
Where two compounds elute within a third of a minute, a mass at this accuracy is what separates them. Retention alone would not have.
quarter_over_quarter
A longitudinal set of retail purchases from one supplier across four quarters is the strongest supplier-level evidence available. Several contributors here are building exactly that.
Section 7

Related records

Same batch — lot WWB-2510-H1662 n=11

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041234WWB-2510-H1662PeptideMeter2026-Q199.504.4699.2Buyer-sourced0PASS
AX-2026-041235WWB-2510-H1662Janoshik2026-Q199.134.7198.6Buyer-sourced0PASS
AX-2026-041236WWB-2510-H1662Janoshik2026-Q199.365.05—Buyer-sourced0PASS
AX-2026-041237WWB-2510-H1662Janoshik2026-Q199.454.60107.2Buyer-sourced0PASS
AX-2026-041238WWB-2510-H1662PeptideMeter2026-Q199.274.62—Buyer-sourced0PASS
AX-2026-041239WWB-2510-H1662Janoshik2026-Q199.685.00103.4Buyer-sourced0PASS
AX-2026-041240WWB-2510-H1662PeptideMeter2026-Q198.964.70—Buyer-sourced0PASS
AX-2026-041241WWB-2510-H1662Janoshik2026-Q199.104.83—Buyer-sourced0PASS
AX-2026-041242WWB-2510-H1662Kestrel2026-Q199.934.97—Buyer-sourced0PASS
AX-2026-041244WWB-2510-H1662Janoshik2026-Q199.144.83—Buyer-sourced0PASS

Cross-sections

Other recent Retatrutide records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042437HomopeptideHOMO-2605-V4718Nordanalyt2026-Q398.683.67102.8Buyer-sourced0PASS
AX-2026-043095KPKP-2607-H5774Janoshik2026-Q395.815.48105.2Buyer-sourced0FAIL
AX-2026-042282TFCTFC-2608-J1156Janoshik2026-Q398.544.27—Buyer-sourced0PASS
AX-2026-043094KPKP-2607-H5774PeptideMeter2026-Q396.326.40—Buyer-sourced0FAIL
AX-2026-042441HomopeptideHOMO-2605-V4718Medutest2026-Q398.934.22—Buyer-sourced0PASS
AX-2026-041427QYBQYB-2604-B4920PeptideMeter2026-Q397.932.45101.7Buyer-sourced0PASS
AX-2026-041786ASYASY-{CAT}-2288VendorInvestigate2026-Q398.786.59—Buyer-sourced0PASS
AX-2026-041428QYBQYB-2604-B4920Janoshik2026-Q398.353.20—Laboratory-retained0PASS
Other recent WWB records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041275LiraglutideWWB-2607-X2189Nordanalyt2026-Q399.334.39—Buyer-sourced1MARGINAL
AX-2026-041334SemaglutideWWB-2606-N3192Janoshik2026-Q398.934.6299.9Buyer-sourced0PASS
AX-2026-041337SemaglutideWWB-2606-N3192Nordanalyt2026-Q399.523.92—Buyer-sourced0PASS
AX-2026-041335SemaglutideWWB-2606-N3192Janoshik2026-Q399.154.2798.9Buyer-sourced0PASS
AX-2026-041271LiraglutideWWB-2607-X2189Medutest2026-Q399.524.5797.4Buyer-sourced1MARGINAL
AX-2026-041328SemaglutideWWB-2606-N3192Janoshik2026-Q398.994.47106.1Buyer-sourced0PASS
AX-2026-041333SemaglutideWWB-2606-N3192Janoshik2026-Q399.184.5190.4Laboratory-retained0PASS
AX-2026-041273LiraglutideWWB-2607-X2189Janoshik2026-Q399.315.52104.8Buyer-sourced1MARGINAL